Renal Cell Carcinoma is a type of kidney cancer that begins in the lining of the small tubes in the kidneys. Making up more than 80% of kidney cancer cases, Renal Cell Carcinoma usually affects men between the ages of 50 to 70. The cause is still unknown, but the symptoms of Renal Cell Carcinoma include abdominal pain, back pain, and weight loss. Renal Cell Carcinoma is usually treated with surgery to remove all infected parts of the kidney and surrounding areas. Chemotherapy and radiation are not often used because of their low effectiveness on kidney cancer. In about one-third of Renal Cell Carcinoma cases, the cancer has spread to other parts of the body.
Renal Cell Carcinoma Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Renal Cell Carcinoma below!
For more information on how to use Laverne, please read the How to Guide.
We have 5197 products for the study of Renal Cell Carcinoma that can be applied to Western Blot, Flow Cytometry, Chromatin Immunoprecipitation, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry, Immunocytochemistry/Immunofluorescence from our catalog of antibodies and ELISA kits.
Renal Cell Carcinoma is also known as renal cell carcinoma, conventional (clear cell) renal cell carcinoma, renal cell carcinoma (morphologic abnormality), renal cell carcinoma, stage unspecified, adenocarcinoma of kidney, hypernephroma (disorder), carcinoma renal cell, adenocarcinoma, carcinoma, rcc.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.